CBMG Cellular Biomedicine Group Inc

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that the Board of the Company has set Friday, November 20, 2015 as the date for the Company’s annual meeting of stockholders, to be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PST, and any and all adjournments or postponements thereof, and authorizes and instructs the designated proxies to vote in the manner directed in the proxy cards received for each stockholder of record as of September 21, 2015, the record date for the meeting.

A stockholder, once having received his/her proxy notice and access card, may view the proxy statement online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59pm, Thursday, November 19, 2015, EST. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to sarah.kelly@CellBioMedGroup.com if you have questions about this proxy voting or have not received your proxy notice card in the mail.

About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of six independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

 

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com